Indberetning af ledende medarbejderes og disses nærtståendes transaktioner med A.P. Møller - Mærsk A/S aktier i forbindelse med aktietilbagekøbsprogram
I forbindelse med det annoncerede aktietilbagekøbsprogram i A.P. Møller - Mærsk A/S sælger A.P. Møller Holding A/S løbende aktier pro rata og markedet informeres følgeligt herom - se vedhæftede fil.
Vedhæftet fil
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Weekly share repurchase program transaction details8.5.2024 18:41:09 CEST | Press release
May 8, 2024 SBM Offshore reports the transaction details related to its EUR65 million (c. US$70 million) share repurchase program for the period May 2, 2024 through May 8, 2024. The repurchases were made under the EUR65 million share repurchase program announced on February 29, 2024 and effective from March 1, 2024. The objective of the program is to reduce share capital. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period March 1, 2024 through May 8, 2024 can be found in the top half of the table below. Further detailed information regarding both the progress of the share repurchase program and all individual transactions can be accessed via the Investors section of the Company’s website. Share Repurchase ProgramOverall progress Share Repurchase Program: Total Repurchase Amount EUR 65,000,000 Cumulative Repurchase Amount EUR 15,064,569 Cumulative Quantity Repurchased 1,059,438 Cumulative
Q3 2023/24 - First sale of the XM30 completed8.5.2024 18:20:00 CEST | Press release
ANNOUNCEMENT NO. 262 Trading statement for Q3 2023/24 (1 January - 31 March 2024) First sale of the XM30 completed Revenue declined by 6% in the third quarter of 2023/24 to DKK 98.9 million from DKK 105.4 million in the year-earlier period. The development reflected continued growth in sales of consumables and services, set off by declining sales of instruments as customers continued to show restraint in purchasing new instruments. EBITDA fell to DKK 43.1 million in the third quarter, being affected by higher staff costs, including non-recurring costs in connection with organisational changes. The EBITDA margin was 44%. In the third quarter, our two new products, the XcytoMatic 40 (XM40) and the XcytoMatic 30 (XM30) attracted satisfactory customer interest, and the first sale of the XM30 was completed. 2023/24Q3Q1-Q3Change, %Change, %Revenue, DKKm98.9-6298.2-14EBITDA, DKKm43.1-23136.2-32EBITDA margin (%)4446 Highlights Revenue declined by 6% in the third quarter of 2023/24 to DKK 98.9
3. kvartal 2023/24 - Første salg af XM30 er gennemført8.5.2024 18:20:00 CEST | pressemeddelelse
MEDDELELSE NR. 262 Periodemeddelelse for 3. kvartal 2023/24 (1. januar - 31. marts 2024) Første salg af XM30 er gennemført Omsætningen faldt i 3. kvartal med 6% til DKK 98,9 mio. mod DKK 105,4 mio. i samme periode sidste år. Udviklingen afspejler en fortsat fremgang i salget af forbrugsvarer og services, mens omsætningen af instrumenter har været faldende som følge af kundernes fortsatte tilbageholdenhed med at købe nye instrumenter. Resultatet af primær drift (EBITDA) faldt i 3. kvartal til DKK 43,1 mio. og var påvirket af øgede personaleomkostninger, herunder engangsomkostninger i forbindelse med organisationsændringer. EBITDA-marginen blev i 3. kvartal på 44%. I 3. kvartal har der været en tilfredsstillende interesse for de to nye produkter, XcytoMatic 40 (XM40) og XcytoMatic 30 (XM30), og det første salg af XM30 er gennemført. 2023/243. kvartal1.-3. kvartalÆndring, %Ændring, %Omsætning, DKK mio.98,9-6298,2-14EBITDA, DKK mio.43,1-23136,2-32EBITDA-margin, %4446 Hovedpunkter Omsætning
International Petroleum Corporation Announces 2024 Annual General Meeting Voting Results8.5.2024 18:00:00 CEST | Press release
International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce the voting results from the Corporation’s 2024 Annual General Meeting of Shareholders held on May 8, 2024 in Calgary, Alberta (the Meeting). Number of Directors The number of Directors of the Corporation was set at eight. Votes For% ForVotes Against% Against62,674,77899.995,3870.01 Election of Directors The eight nominees listed in the Corporation’s management information circular dated March 22, 2024 (the Circular) were elected as Directors of the Corporation to hold office until the next annual meeting of shareholders or until their successors are duly elected or appointed, unless the office is earlier vacated, as described in the Circular. NomineeVotes For% ForVotes Withheld% WithheldC. Ashley Heppenstall61,390,66198.101,187,5871.90William Lundin62,290,86899.54287,3800.46Chris Bruijnzeels62,177,25599.36400,9930.64Donald Charter55,737,08589.076,841,16310.93Lukas H. (Harry
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons8.5.2024 17:31:01 CEST | Press release
Bagsværd, Denmark, 8 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonMaziar Mike Doustdar2 Reason for the notificationa)Position/statusExecutive Vice Presidentb)Initial notification/AmendmentInitial notification3 Details of the issuera)NameNovo Nordisk A/Sb)LEI549300DAQ1CVT6CXN342